Top Story

ODYSSEY LONG TERM hints at reduction in CV events with alirocumab

September 1, 2014

Read the Perspective from Christie M. Ballantyne, MD

BARCELONA, Spain — Long-term results indicate that in addition to reducing cholesterol on top of regular statin therapy, treatment with alirocumab also reduced the incidence of CV events.

The ODYSSEY LONG TERM trial included 2,431 patients with hypercholesterolemia (≥70 mg/dL at baseline) at high or very high CV risk, including those with heterozygous familial hypercholesterolemia (18%). Researchers randomly assigned each patient to receive a subcutaneous injection of alirocumab 150 mg every 2 weeks (n=1,553) or matching placebo (n=788). Both groups were also treated with maximally tolerated statin therapy and some patients received additional lipid-lowering therapy.

All patients have been followed for 52 weeks and follow-up is ongoing. Jennifer G. Robinson, MD, MPH, presented data at ESC Congress from a mean follow-up of 65 weeks.

figure Meeting News CoveragePerspective

Alirocumab bests ezetimibe for LDL reduction in ODYSSEY studies

August 31, 2014
BARCELONA, Spain — New data from the ODYSSEY clinical trials program demonstrate significant LDL reductions with the investigational PCSK9 inhibitor alirocumab…
Meeting News CoveragePerspective

SOLID-TIMI 52: Darapladib after ACS did not lower risk for subsequent events

August 31, 2014
BARCELONA, Spain — After ACS, direct inhibition of lipoprotein-associated phospholipase A2 with darapladib failed to reduce the risk for coronary events when…
figure Meeting News Coverage

COPPS-2: Perioperative colchicine reduced incidence of postpericardiotomy syndrome

August 30, 2014
BARCELONA, Spain — Perioperative use of oral colchicine reduced the incidence of postpericardiotomy syndrome in patients undergoing cardiac surgery, but did not…
CME

Practical Lipidology: 2013

This activity is supported by an educational grant from Genentech.

12/1/2013
The rise in the prevalence of obesity in the last few decades and its growing impact on health has driven the…
More »
Meeting News Coverage Video
figure

Dominic A. Sica, MD, on treatment for resistant hypertension

June 6, 2014
NEW YORK — In this video, Dominic A. Sica, MD, chairman of clinical pharmacology and hypertension at the…
More »
CME

Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control

This activity is supported by an educational grant from Genentech.

2/1/2014
Among the multiple comorbidities and complications that are associated with type 2 diabetes mellitus (T2DM)…
More »

Filter By:

figure Meeting News Coverage Perspective

ODYSSEY LONG TERM hints at reduction in CV events with alirocumab

September 1, 2014
BARCELONA, Spain — Long-term results indicate that in addition to reducing cholesterol on top of regular statin therapy, treatment with…
figure Meeting News Coverage Perspective

Alirocumab bests ezetimibe for LDL reduction in ODYSSEY studies

August 31, 2014
BARCELONA, Spain — New data from the ODYSSEY clinical trials program demonstrate significant LDL reductions with the investigational PCSK9…
Meeting News Coverage Perspective

SOLID-TIMI 52: Darapladib after ACS did not lower risk for subsequent events

August 31, 2014
BARCELONA, Spain — After ACS, direct inhibition of lipoprotein-associated phospholipase A2 with darapladib failed to reduce the risk for…
figure Meeting News Coverage

COPPS-2: Perioperative colchicine reduced incidence of postpericardiotomy syndrome

August 30, 2014
BARCELONA, Spain — Perioperative use of oral colchicine reduced the incidence of postpericardiotomy syndrome in patients undergoing cardiac…
In the Journals

Excessive exercise increased CVD mortality risk among MI survivors

August 29, 2014
Running or walking progressively decreased risk for CVD-related mortality among survivors of prior MI up to a certain point, but excessive exercise…
FDA News

Amgen files BLA for evolocumab to treat high cholesterol

August 28, 2014
Amgen announced that it has submitted a Biologics License Application to the FDA for its PCSK9 inhibitor evolocumab, seeking approval for the…
In the Journals

No association found between lipid levels, pathway genes and AMD progression

August 27, 2014
Results from a meta-analysis showed no associations between cholesterol measures, history of statin use or lipid pathway genes and the incidence and…
In the Journals

USPSTF recommends intensive behavioral counseling for people with obesity, overweight

August 26, 2014
People who are obese or overweight with at least one other cardiovascular disease risk factor should receive intensive behavioral counseling focusing…
In the Journals

New cholesterol guideline improved accuracy of statin assignment vs. previous guideline

August 26, 2014
The 2013 American Heart Association/American College of Cardiology guideline on the assessment of CV risk more closely matched statin assignment to…

USPSTF recommends behavioral counseling for obese, overweight people at risk for CVD

August 25, 2014
The United States Preventive Services Task Force recommended that adults who are overweight or obese and have at least one risk factor for CVD be…
More Headlines »